<DOC>
	<DOCNO>NCT01818479</DOCNO>
	<brief_summary>Open label , dose find trial two treatment arm ( high-TBI low-TBI conditioning regimen ) assess efficacy Treg/Tcon addback CD34 select partially match relate donor stem cell . The maximum tolerate dose establish use 3 patient per dose level expansion cohort MTD .</brief_summary>
	<brief_title>Phase I/II Study Treg/Tcon Addback CD34 Selected Partially Matched Related Donor Stem Cells With Myeloablative Conditioning High Risk Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Age 070 year 2 . Karnofsky Lansky Performance status &gt; 70 % 3 . High risk hematologic malignancy 4 . Acute myeloid leukemia ( AML ) one follow criterion : 4a.Poor risk cytogenetics , include 5 , 5q , 7 , 7q , ( 9 ; 22 ) ; complex cytogenetics ( &gt; 3 abnormality ) ; normal cytogenetics Flt3 ITD , first subsequent complete remission ( CR ) . 4b . Relapsed primary refractory AML &lt; 10 % blast peripheral blood . 4c . Patients CR1 require two cycle induction achieve remission may include discretion treat physician . 4d . Standard risk intermediate risk cytogenetics second subsequent CR ( enrol discretion treat physician ) . 5 . Acute lymphoblastic leukemia ( ALL ) one follow criterion : 5a . Second subsequent CR 5b . Any PR ( circulate blast ) 5c . Highrisk ALL first CR include ( Ph+ , ( 4:11 ) , complex karyotype , hypodiploidy ( &lt; 44 chromosome ) , positive MRD induction 6 . Myelodysplasia , intermediate 2 ( score 1.52.0 ) high risk ( score &gt; 2.5 ) International Prognostic Score System . 7 . Myeloproliferative Disorders ( include CMML , AMM Idiopathic Myelofibrosis , JMML ) excess blast ( &gt; 5 % ) 8 . Chronic myeloid leukemia ( CML ) one follow criterion : 8a . Second subsequent chronic phase 8b . Accelerated phase 8c . blast crisis 9 . NonHodgkin 's lymphoma ( NHL ) meet one follow criterion : 9a . Relapse autologous stem cell transplantation evidence responsive disease . 9b . Patient chemosensitive relapse option autologous stem cell transplantation due blood marrow involvement failure mobilize autologous stem cell consider eligible autologous transplant treat physician . 9c . Hodgkin 's Lymphoma : relapse autologous HCT , chemorefractory disease 10 . No suitable HLAidentical sibling donor . 11 . No identified 8/8 ( base upon A , B , C , DRB1 locus ) allele match unrelated donor , unable wait sufficient time procure 8/8 allele match unrelated donor 12 . Available HLA 35/6 match genotypically haploidentical partially match relate donor 13 . Female patient must surgically sterile , postmenopausal ( minimum 1 year without menses ) , agree use approve form contraception time sign informed consent form Day +100 . Male patient must also agree use approved form birth control either partner , appropriate , time signing informed consent form Day +100 . 14 . Able provide inform consent sign approve consent form conform federal institutional guideline . 1 . Available HLA identical match sibling donor ( unless fail prior allogeneic transplant HLA identical match sibling ) 2 . Recipient HLA antibody donor HLA 3 . Any following organ dysfunction : 1 . Cardiac leave ventricular ejection fraction &lt; 40 % , symptomatic coronary artery disease , uncontrolled arrhythmias 2 . Pulmonary FEV1 DLco &lt; 40 % need use supplemental oxygen 3 . Renal calculate measure GFR &lt; 30 ml/min , dialysis requirement , prior renal transplant 4 . Hepatic bilirubin &gt; 2 X ULN , ALT &gt; 2.5 X ULN , cirrhosis 4 . Patients active uncontrolled bacterial , viral , fungal infection require systemic therapy . 5 . Patients test positive HIV . 6 . Pregnant woman , nurse mother woman childbearing potential unwilling use medically accept method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>